Spiro George Rombotis - 13 Dec 2021 Form 4/A - Amendment Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
President and CEO, Director
Signature
/s/ Spiro Rombotis
Issuer symbol
CYCC
Transactions as of
13 Dec 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
16 Dec 2021, 15:16:22 UTC
Date Of Original Report
15 Dec 2021
Previous filing
22 Nov 2021
Next filing
02 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Stock Option (right to buy) Award $0 +190,000 $0.000000 190,000 13 Dec 2021 Common Stock 190,000 $3.45 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis.
F2 These securities were granted as part of the Issuer's annual compensation review to executive officers.
F3 This Form 4 is being amended to correct a typographical error in the number of shares of Common Stock underlying the options granted to the reporting person on December 13, 2021. 190,000 shares of Common Stock underlie the granted options.